Liontrust GF UK Growth Fund

• BAE Systems the top portfolio riser as aerospace & defence sector leads market on expectations of greater military spending in Europe.
• Healthcare holdings also strengthen as defensive areas fare well in February.
• Setbacks at Renishaw and Indivior drag on monthly performance.

The Liontrust GF UK Growth Fund returned -1.7%* in February. The Fund’s comparator benchmark, the FTSE All-Share, returned 1.3%.

Mounting geopolitical instability was reflected in aerospace & defence’s position at the top of the FTSE All-Share’s sector breakdown for February – up 18% in total return terms. President Trump’s approach to the Ukrainian conflict has included calling for a swift end to the war, criticising President Zelensky and indicating an unwillingness to continue financial and military assistance. As a result, investors are factoring in higher expectations of military spending in Europe from governments attempting to fill the void and deter Russian aggression.

Ongoing uncertainty over trade tariffs also contributed to macroeconomic nervousness. Equity markets sold off in the first days of February as Trump announced a range of tariffs on Canada and Mexico, only to defer them a couple of days later having won some concessions on matters including border security. This added to investor confusion over whether Trump’s tariff threats are statements of true intent or negotiating tools.

Within the Fund, the top riser was BAE Systems (+15%), rallying alongside global defence peers. The healthcare sector was another area of strength for the portfolio as defensive areas performed well. The release of full-year results sparked solid rallies at AstraZeneca (+7.0%), Haleon (+6.3%), GSK (+5.5%) and Convatec Group (+5.0%).

AstraZeneca recorded 25% constant currency growth in Q4 sales to take its 2024 total to over $ 54 billion – up by 21%. The performance was ahead of consensus expectations, driven by a 41% expansion in oncology sales. For 2025, AstraZeneca expects a high single-digit percentage increase in revenues, with earnings per share rising by a low double-digit percentage. It was a similar story of growth modestly beating expectations and solid forward guidance from Haleon, GSK and Convatec Group (the latter a recent new addition to the Fund).

Overall, however, when compared with the FTSE All-Share Index, the Fund faced similar headwinds to those present during much of 2024; namely, the outperformance of large-caps versus small and mid-caps, particularly among banks, a sector the Fund does not own. The banks sub-sector was the second strongest in February behind aerospace & defence, rising 11%.

We have previously written at length about the tough relative performance environment at the back end of last year, as well as the mounting potential for outperformance from some of the more unloved areas of the market as and when sentiment recovers and valuations revert towards long-term averages.

Compounding these negative attribution trends were a couple of stock-specific setbacks which tipped overall Fund performance into negative territory for the month. 

Renishaw (-20%) has been contending with cyclical weakness in many of its industrial end markets. The specialist in high-tech precision engineering for metrology and healthcare commented in February’s half-year results that order intake has recently improved, but investors focused instead on a deterioration in quarterly sales. A slowdown in its second quarter meant that six-monthly sales rose only 3% year-on-year to £341 million, with profit before tax rising 2% to £57.5 million – both below expectations. Although Renishaw says it has seen improved order trends, particularly from semiconductor and consumer electronics customers, its 2025 guidance also fell short of investor expectations.

While the Fund’s healthcare exposure was a strong positive overall, it did include a sharp fall for Indivior’s (-27%) shares. The pharmaceutical group has recently been the subject of activist investor intervention, prompting a strategic refocusing around its core opioid use disorder (OUD) products and pipeline assets, as well as significant board and executive management change. 2024 results announced in February were ahead of previously downgraded consensus expectations but nevertheless included extremely cautious guidance for the current financial year, potentially heralding a welcome change in the company’s approach to forecasting.

Positive contributors included:

BAE Systems (+15%), AstraZeneca (+7.0%), Haleon (+6.3%), GSK (+5.5%) and Convatec Group (+5.0%).

Negative contributors included:

Indivior (-27%), Renishaw (-20%), Sage Group (-11%), Spirax Group (-10%) and Diageo (-9.2%)

Discrete years' performance** (%) to previous quarter-end:

Past performance does not predict future returns

*Source: Financial Express, as at 28.02.25, total return (net of fees and income reinvested), sterling terms, C3 institutional class. Non fund-related return data sourced from Bloomberg. **Source: Financial Express, as at 31.12.24, total return (net of fees and income reinvested), primary class. Investment decisions should not be based on short-term performance.      

KEY RISKS

Past performance is not a guide to future performance. The value of an investment and the income generated from it can fall as well as rise and is not guaranteed. You may get back less than you originally invested.

The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term.

Past performance does not predict future returns. You may get back less than you originally invested.

We recommend this fund is held long term (minimum period of 5 years). We recommend that you hold this fund as part of a diversified portfolio of investments.

• The Fund may encounter liquidity constraints from time to time. The spread between the price you buy and sell shares will reflect the less liquid nature of the underlying holdings.
• The Fund may invest in companies listed on the Alternative Investment Market (AIM) which is primarily for emerging or smaller companies. The rules are less demanding than those of the official List of the London Stock Exchange and therefore companies listed on AIM may carry a greater risk than a company with a full listing.
• Outside of normal conditions, the Fund may hold higher levels of cash which may be deposited with several credit counterparties (e.g. international banks). A credit risk arises should one or more of these counterparties be unable to return the deposited cash.
• Counterparty Risk: any derivative contract, including FX hedging, may be at risk if the counterparty fails.

DISCLAIMER

This material is issued by Liontrust Investment Partners LLP (2 Savoy Court, London WC2R 0EZ), authorised and regulated in the UK by the Financial Conduct Authority (FRN 518552) to undertake regulated investment business.

It should not be construed as advice for investment in any product or security mentioned, an offer to buy or sell units/shares of Funds mentioned, or a solicitation to purchase securities in any company or investment product. Examples of stocks are provided for general information only to demonstrate our investment philosophy. The investment being promoted is for units in a fund, not directly in the underlying assets.

This information and analysis is believed to be accurate at the time of publication, but is subject to change without notice. Whilst care has been taken in compiling the content, no representation or warranty is given, whether express or implied, by Liontrust as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified.

This is a marketing communication. Before making an investment, you should read the relevant Prospectus and the Key Investor Information Document (KIID) and/or PRIIP/KID, which provide full product details including investment charges and risks. These documents can be obtained, free of charge, from www.liontrust.co.uk or direct from Liontrust. If you are not a professional investor please consult a regulated financial adviser regarding the suitability of such an investment for you and your personal circumstances.